Conatus Pharmaceuticals ROA 2012-2018 | CNAT

Current and historical return on assets (ROA) values for Conatus Pharmaceuticals (CNAT) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Conatus Pharmaceuticals ROA for the three months ending September 30, 2018 was -26.03%.
Conatus Pharmaceuticals ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-09-30 $-0.02B $0.06B -25.35%
2018-06-30 $-0.02B $0.07B -21.59%
2018-03-31 $-0.02B $0.08B -20.75%
2017-12-31 $-0.02B $0.08B -19.21%
2017-09-30 $-0.02B $0.09B -24.86%
2017-06-30 $-0.03B $0.10B -33.56%
2017-03-31 $-0.03B $0.08B -45.02%
2016-12-31 $-0.03B $0.08B -63.39%
2016-09-30 $-0.03B $0.03B -73.76%
2016-06-30 $-0.03B $0.03B -65.36%
2016-03-31 $-0.03B $0.04B -58.82%
2015-12-31 $-0.02B $0.04B -57.83%
2015-09-30 $-0.02B $0.05B -56.10%
2015-06-30 $-0.02B $0.05B -56.79%
2015-03-31 $-0.02B $0.03B -54.66%
2014-12-31 $-0.02B $0.04B -65.12%
2014-09-30 $-0.02B $0.04B -56.76%
2014-06-30 $-0.02B $0.05B -68.57%
2014-03-31 $-0.01B $0.00B -91.23%
2013-12-31 $-0.01B $0.06B -70.18%
2013-09-30 $-0.01B $0.00B -250.00%
2013-06-30 $-0.01B $0.00B -250.00%
2013-03-31 $-0.01B $0.00B -350.00%
2012-12-31 $-0.01B $0.01B -250.00%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.148B $0.035B
Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Conatus Pharmaceuticals, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $124.342B 19.06
Abbott Laboratories (ABT) United States $122.048B 24.73
Stryker (SYK) United States $62.796B 23.67
Boston Scientific (BSX) United States $50.730B 25.64
Baxter (BAX) United States $33.541B 21.66
Zimmer Biomet Holdings (ZBH) United States $23.031B 14.94
Smith & Nephew SNATS (SNN) United Kingdom $16.007B 0.00
ResMed (RMD) United States $14.492B 27.64
Canopy Growth (CGC) Canada $8.934B 0.00
Perrigo (PRGO) Ireland $8.884B 13.48
Bio-Rad Laboratories (BIO) United States $8.054B 51.50
Aurora Cannabis (ACB) Canada $6.462B 35.26
Hill-Rom Holdings (HRC) United States $6.201B 19.66
Haemonetics (HAE) United States $5.495B 48.33
Insulet (PODD) United States $4.770B 0.00
ICU Medical (ICUI) United States $4.529B 25.23
Hutchison China MediTech (HCM) China $4.274B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.987B 0.00
Agios Pharmaceuticals (AGIO) United States $3.869B 0.00
Neogen (NEOG) United States $3.219B 48.74
National Vision Holdings (EYE) United States $3.101B 61.33
NuVasive (NUVA) United States $2.972B 27.65
Aphria (APHA) $2.572B 0.00
Quidel (QDEL) United States $2.478B 32.30
NxStage Medical (NXTM) United States $1.924B 0.00
Phibro Animal Health (PAHC) United States $1.476B 20.89
AtriCure (ATRC) United States $1.174B 0.00
Cardiovascular Systems (CSII) United States $1.015B 1462.50
VAREX IMAGING (VREX) United States $0.992B 19.93
Meridian Bioscience (VIVO) United States $0.827B 26.35
PetIQ (PETQ) United States $0.803B 22.83
OraSure Technologies (OSUR) United States $0.793B 44.65
Surmodics (SRDX) United States $0.776B 118.55
Eagle Pharmaceuticals (EGRX) United States $0.755B 24.22
Cerus (CERS) United States $0.719B 0.00
MacroGenics (MGNX) United States $0.710B 0.00
Omeros (OMER) United States $0.623B 0.00
Lantheus Holdings (LNTH) United States $0.590B 18.27
Owens & Minor (OMI) United States $0.558B 6.31
Insys Therapeutics (INSY) United States $0.542B 0.00
LeMaitre Vascular (LMAT) United States $0.518B 25.45
NanoString Technologies (NSTG) United States $0.481B 0.00
TG Therapeutics (TGTX) United States $0.438B 0.00
Evolus (EOLS) United States $0.399B 0.00
Quanterix (QTRX) United States $0.359B 0.00
Utah Medical Products (UTMD) United States $0.327B 21.12
Cytosorbents (CTSO) United States $0.302B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.255B 0.00
Surface Oncology (SURF) United States $0.226B 0.00
Rockwell Medical (RMTI) United States $0.211B 0.00
BioLife Solutions (BLFS) United States $0.206B 278.75
Bovie Medical (BVX) United States $0.201B 0.00
Chimerix (CMRX) United States $0.161B 0.00
Fonar (FONR) United States $0.139B 6.96
Chembio Diagnostics (CEMI) United States $0.104B 0.00
Imprimis Pharmaceuticals (IMMY) United States $0.081B 0.00
United-Guardian (UG) United States $0.079B 16.63
Female Health (VERU) United States $0.079B 0.00
Trinity Biotech (TRIB) Ireland $0.077B 24.40
Oramed Pharmaceuticals (ORMP) Israel $0.070B 0.00
InfuSystems Holdings (INFU) United States $0.067B 0.00
CAS Medical Systems (CASM) United States $0.056B 0.00
Neurotrope (NTRP) United States $0.050B 0.00
ImmuCell (ICCC) United States $0.041B 0.00
Capricor Therapeutics (CAPR) United States $0.028B 0.00
Myomo (MYO) United States $0.025B 0.00
Valeritas Holdings (VLRX) United States $0.021B 0.00
Senestech (SNES) United States $0.019B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.019B 0.00
Cellectar Biosciences (CLRB) United States $0.009B 0.00
NeuroMetrix (NURO) United States $0.007B 0.00
Akers Biosciences Inc (AKER) United States $0.000B 0.00